Elisangela Oliveira de Freitas
Analysis of the immunogenicity of recombinant proteins based on different allelic forms of the circumsporozoite antigen of Plasmodium vivax for the development of universal vaccine malaria
Plasmodium vivax is the second most prevalent species causing malaria in the world. Recent data estimates the occurrence of cases 132-391 million annually. The relative inefficiency of control measures currently employed requires the development of new prevention strategies, such as vaccines, new drugs and new insecticides. Studies in the past 20 years to the development a recombinant vaccine against human infection caused by Plasmodium falciparum antigen were based on the circumsporozoite protein (CS). In work recently published phase III clinical trials conducted with children African reported an efficacy of about 50%. These proteins and adenoviruses have been successfully used in prime-boost protocols (adenovirus / recombinant protein) in experimental models mice are able to induce immunity against the three allelic forms of CS protein of P. vivax.
In this project, our goal is to continue our studies for the development of a universal vaccine against P. vivax. Thus, we aim test whether these vaccinations are actually able to protect mice against challenge with P. berghei transgenic parasites of the species expressing CS protein of P. vivax.